TARA-002 achieved a 72% complete response rate in BCG-naive NMIBC patients, with durable responses at 6 and 12 months. The ...
Additionally, beyond adapting existing drug combinations, cutting-edge therapies such as bispecific antibodies and CAR T-cell ...
QBS72S, a LAT1-targeted agent, shows potential in treating leptomeningeal disease, improving survival rates in metastatic ...
LP-184 shows promising efficacy and safety in heavily pretreated advanced cancer patients, paving the way for innovative ...
JANX007 shows significant PSA reductions and favorable rPFS in mCRPC patients, with a manageable safety profile. The trial identifies 6 mg and 9 mg as optimal doses, balancing safety and efficacy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback